Navigation Links
Cell Therapeutics to Host Conference Call Today, Friday, November 15, 2013, at 8:30 a.m. Eastern Time, to Discuss Pacritinib Partnership
Date:11/15/2013

SEATTLE, Nov. 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that members of management will host a conference call today, Friday, November 15, 2013 at 8:30 a.m. ET (5:30 a.m. PT) to discuss today's announcement regarding the worldwide licensing agreement between Baxter International, Inc. and CTI to develop and commercialize pacritinib, CTI's novel investigational JAK2/FLT3 inhibitor currently in Phase 3 development for patients with myelofibrosis.  Access to the event can be obtained as follows:

Friday, November, 15, 2013
5:30 a.m. PT/8:30 a.m. ET/2:30 p.m. CET
1-800-762- 8779(domestic)
+1 480-629-9645 (international)

To access the live audio webcast or the subsequent archived recording, visit www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international). The access code for the replay is 4651503. The telephone replay will be available until Friday, November 22, 2013.

About Cell Therapeutics, Inc.
Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In Europe
CTI Life Sciences Limited, Milan Branch
Laura Villa
T: +39 02 89659706
E: lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
2. PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results
3. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
4. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
5. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
6. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
7. Sorrento Therapeutics Adopts Stockholder Rights Plan
8. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
9. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
10. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
11. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... --  PDI , a leader in infection prevention products ... session focused on the role of chlorhexidine gluconate (CHG) ... 2017 Annual Scientific Meeting of the Association for Vascular ... Phoenix Convention Center in ... also feature PDI,s Prevantics® Device Swab as ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and ... DoseCheck solution. Scannerside DoseCheck is a third-party Vendor neutral ... CT scanners and allows compliance with current MITA standards. ... proprietary XR 29 DoseCheck solution is specifically designed to ... alerts of potential radiation doses over a predefined threshold. ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... ... tick-borne diseases through research, education and awareness, today announced the appointment of Timothy ... and microbiologist, Dr. Sellati has more than 20 years of research experience with ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      ... things wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing ... in compliance with FDA rules. , The FDA has issued two draft guidances ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create ... back to the community. For over 37 years, they have operated with their mission ... plumbing in San Diego. They were chosen as the Best San Diego plumber ...
(Date:9/21/2017)... Southborough, Mass. (PRWEB) , ... September 21, 2017 , ... ... for children with autism, announced today the election of Yie-Hsin Hung to the Board ... Yie-Hsin Hung join our Board of Directors. Ms. Hung is an invaluable addition to ...
Breaking Medicine News(10 mins):